Journal article
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
Y Xu, JCH Yang, Y Zhao, L Doucet, J Zhou, Y Wang, D Planchard, Y Fan, B Jin, Z Han, L Greillier, J Mazieres, M Sun, Y Hu, X Song, C Ding, L Wu, K Tang, L Liang, Y Yao Show all
Cell Reports Medicine | Published : 2025
Open access
Abstract
This is a report of biomarker analysis for sunvozertinib, a leading epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion mutation (exon20ins) non-small cell lung cancer (NSCLC). There is a positive correlation between positive EGFR exon20ins in plasma circulating tumor DNA (ctDNA) and advanced disease. Shorter progression-free survival and lower objective response rate (45.8% vs. 68.0%) were observed in patients with positive EGFR exon20ins compared to those with negative status. Droplet digital PCR analysis showed that the EGFR exon20ins allele in ctDNA decreased over time in 85.7% of patients, with the earliest clearance occurred after 1 ..
View full abstract